Comirnaty: Clinical Trials

5 trials of Comirnaty, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 terminated, 1 unknown, 1 withdrawn. 5 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 35Completed 2, Terminated 1, Unknown 1, Withdrawn 1

Follow Comirnaty: new trials by email Literature Review of Comirnaty trials Research Report on Comirnaty

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Evaluation of COVID-19 Vaccines Given as a Booster in Healthy Adults in Indonesia (MIACoV Indonesia)
Pfizer-BioNTech Standard dose, AstraZeneca Standard dose, Pfizer-BioNTech Fractional dose - COVID-19
Phase 3WithdrawnMurdoch Childrens Research Institute2024-04-012024-03-22
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2
ABNCoV2, Comirnaty - COVID-19 Disease
Phase 3CompletedBavarian Nordic42052022-08-302025-02-24
A Study to Evaluate the Immunogenicity and Safety of Two Recombinant Protein COVID-19 Vaccines in Population Aged ≥18 Years as Booster Vaccines
SCTV01C, SCTV01E, Sinopharm inactivated COVID-19 vaccine - COVID-19, SARS-CoV-2 Infection
Phase 3UnknownSinocelltech Ltd.18002022-05-302023-04-10
Evaluation of Full Versus Fractional Dose of COVID-19 Vaccine Given as a Booster for the Prevention of COVID-19 in Adults in Mongolia.
Tozinameran - Standard Dose, Tozinameran - Fractional Dose - COVID-19
Phase 3CompletedMurdoch Childrens Research Institute6012022-05-272026-03-24
Evaluation of Full Versus Fractional Doses of COVID-19 Vaccines Given as a Booster in Adults in Australia - Mongolia, Indonesia, Australia Coronavirus (MIACoV).
Tozinameran - Standard dose, Tozinameran - fractional dose, Elasomeran - standard dose - COVID-19
Phase 3TerminatedMurdoch Childrens Research Institute132022-05-022024-12-16

Conditions studied

COVID-19 (4)

Sponsors

Murdoch Childrens Research Institute (3)  ·  Bavarian Nordic (1)  ·  Sinocelltech Ltd. (1)

Countries

Australia (1)  ·  Belgium (1)  ·  Denmark (1)  ·  Indonesia (1)  ·  Mongolia (1)  ·  United Arab Emirates (1)  ·  United States (1)

Top investigators

Eddy Fadlyana, Dr (1)  ·  Kim Mulholland, MD (1)  ·  Kim Mulholland, MD/Prof (1)  ·  Leo James, MD (1)  ·  Tsetsegsaikhan Batmunkh, MD (1)

Results publications

PMID 36598621, PMID 37731938, PMID 38357398, PMID 41072276, PMID 41948336